申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP2883865A1
公开(公告)日:2015-06-17
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like.
wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
具有与 S1P 受体(特别是 EDG-6,优选 EDG-1 和 EDG-6)结合能力的化合物,例如本发明式 (I) 所代表的化合物、其盐、其溶液或其原药,可用于预防和/或治疗移植排斥反应、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病等。
其中,环 A 是环状基团;环 B 是可具有取代基的环状基团;X 是在其主链中具有 1 至 8 个原子的间隔物等;Y 是在其主链中具有 1 至 10 个原子的间隔物等;n 是 0 或 1,其中,当 n 是 0 时,m 是 1,R1 是氢原子或取代基,当 n 是 1 时,m 是 0 或 1 至 7 的整数,R1 是取代基,其中,m 是 2 或更多,R1s 相同或不同。